Diabetes, prediabetes and cardiovascular risk
暂无分享,去创建一个
[1] J. Shaw,et al. Risk of Cardiovascular and All-Cause Mortality in Individuals With Diabetes Mellitus, Impaired Fasting Glucose, and Impaired Glucose Tolerance: The Australian Diabetes, Obesity, and Lifestyle Study (AusDiab) , 2007, Circulation.
[2] S. Yusuf,et al. Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: the ORIGIN Trial (Outcome Reduction with an Initial Glargine Intervention). , 2008, American heart journal.
[3] A. Hungin,et al. Impaired glucose tolerance: qualitative and quantitative study of general practitioners' knowledge and perceptions , 2002, BMJ : British Medical Journal.
[4] A. Hamsten,et al. Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study , 2002, The Lancet.
[5] Oluf Pedersen,et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. , 2003, The New England journal of medicine.
[6] R. Klein,et al. Onset of NIDDM occurs at Least 4–7 yr Before Clinical Diagnosis , 1992, Diabetes Care.
[7] R. Holman,et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study , 2000, BMJ : British Medical Journal.
[8] J. Tuomilehto,et al. Two-hour glucose is a better risk predictor for incident coronary heart disease and cardiovascular mortality than fasting glucose. , 2002, European heart journal.
[9] L. Rydén,et al. Evidence-based medication and revascularization: powerful tools in the management of patients with diabetes and coronary artery disease: a report from the Euro Heart Survey on diabetes and the heart , 2008, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.
[10] S. Yusuf,et al. The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. , 1999, Diabetes care.
[11] H. Gerstein,et al. Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: the ORIGIN Trial (Outcome Reduction with an Initial Glargine Intervention). , 2008, American heart journal.
[12] G. Rossi,et al. Diagnosis and Classification of Diabetes Mellitus The information that follows is based largely on the reports of the Expert Committee on the Diagnosis and Classification of Diabetes (Diabetes Care 20:1183–1197, 1997, and Diabetes Care 26:3160–3167, 2003). , 2008, Diabetes Care.
[13] H. Keen,et al. HYPERGLYCÆMIA AND DIABETES MELLITUS , 1976, The Lancet.
[14] Beverley Balkau,et al. High Blood Glucose Concentration Is a Risk Factor for Mortality in Middle-Aged Nondiabetic Men: 20-year follow-up in the Whitehall Study, the Paris Prospective Study, and the Helsinki Policemen Study , 1998, Diabetes Care.
[15] L. V. Van Gaal,et al. Rimonabant as an adjunct therapy in overweight/obese patients with type 2 diabetes. , 2007, European heart journal.
[16] D. Hu,et al. The relationship between coronary artery disease and abnormal glucose regulation in China: the China Heart Survey. , 2006, European heart journal.
[17] K. Yano,et al. Glucose intolerance and 23-year risk of coronary heart disease and total mortality: the Honolulu Heart Program. , 1999, Diabetes care.
[18] U. Zeymer,et al. Effect of acarbose treatment on the risk of silent myocardial infarctions in patients with impaired glucose tolerance: results of the randomised STOP-NIDDM trial electrocardiography substudy , 2004, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.
[19] D. Mills,et al. STARCH EMBOLI IN TRANSPLANTED KIDNEYS , 1974 .
[20] J. A. Hunt,et al. Variation of Postprandial Plasma Glucose, Palatability, and Symptoms Associated With a Standardized Mixed Test Meal Versus 75 g Oral Glucose , 1998, Diabetes Care.
[21] L. Rydén,et al. Diabetes known or newly detected, but not impaired glucose regulation, has a negative influence on 1-year outcome in patients with coronary artery disease: a report from the Euro Heart Survey on diabetes and the heart. , 2006, European heart journal.
[22] E. Feskens,et al. Glucose tolerance and mortality: comparison of WHO and American Diabetic Association diagnostic criteria , 1999, The Lancet.
[23] F. Ovalle. 10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes , 2009 .
[24] M. Laakso,et al. Understanding patient needs Diabetology for cardiologists , 2003 .
[25] M. Harris,et al. Diabetes and decline in heart disease mortality in US adults. , 1999, JAMA.
[26] Maria Mori Brooks,et al. A randomized trial of therapies for type 2 diabetes and coronary artery disease. , 2009, The New England journal of medicine.
[27] Roberto Ferrari,et al. The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe. The Euro Heart Survey on diabetes and the heart. , 2004, European heart journal.
[28] M. Shipley,et al. CORONARY-HEART-DISEASE RISK AND IMPAIRED GLUCOSE TOLERANCE The Whitehall Study , 1980, The Lancet.
[29] M. Laakso,et al. Diabetology for cardiologists , 2003 .
[30] Copeman Pw,et al. THE AMERICAN AND HIS DIET. , 1964 .
[31] L. Rydén,et al. The impact of infarct type on the reliability of early oral glucose tolerance testing in patients with myocardial infarction. , 2010, International journal of cardiology.
[32] L. Rydén,et al. Oral Glucose Tolerance Test: A Reliable Tool for Early Detection of Glucose Abnormalities in Patients With Acute Myocardial Infarction in Clinical Practice , 2008, Diabetes Care.
[33] L. Rydén,et al. Oral glucose tolerance test is needed for appropriate classification of glucose regulation in patients with coronary artery disease: a report from the Euro Heart Survey on Diabetes and the Heart , 2006, Heart.
[34] V. Mohan. Cardiovascular risk profile assessment in glucose‐intolerant Asian individuals—an evaluation of the World Health Organization two‐step strategy: the DECODA Study (Diabetes Epidemiology: Collaborative Analysis of Diagnostic Criteria in Asia) , 2002, Diabetic medicine : a journal of the British Diabetic Association.
[35] O. Pedersen,et al. Effect of a multifactorial intervention on mortality in type 2 diabetes. , 2008, The New England journal of medicine.
[37] Peter Lindgren,et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary , 2007 .
[38] M. Hanefeld,et al. Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. , 2004, European heart journal.
[39] E. Feskens,et al. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. , 2001, Archives of internal medicine.
[40] Markolf Hanefeld,et al. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. , 2003, JAMA.
[41] M. Laakso,et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial , 2006, The Lancet.
[42] T. Valle,et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. , 2001, The New England journal of medicine.
[43] A. Lindahl,et al. Undiagnosed dysglycaemia and inflammation in cardiovascular disease , 2006, European journal of clinical investigation.
[44] S. Fowler,et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. , 2002 .
[45] K. Malmberg,et al. Diabetes mellitus: the major risk factor in unstable coronary artery disease even after consideration of the extent of coronary artery disease and benefits of revascularization. , 2004, Journal of the American College of Cardiology.
[46] S. Lamont,et al. Screening for Type 2 diabetes: is it worthwhile? Views of general practitioners and practice nurses , 2003, Diabetic medicine : a journal of the British Diabetic Association.
[47] L. Rydén,et al. Glucose lowering treatment in patients with coronary artery disease is prognostically important not only in established but also in newly detected diabetes mellitus: a report from the Euro Heart Survey on Diabetes and the Heart. , 2007, European heart journal.